Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maxamine plus IL-2 in AML Remission
NCT00003991Phase 3Completed
- Sponsor
- Maxim Pharmaceuticals
- Start
- Jul 1998
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of histamine dihydrochloride in acute myeloid leukemia (AML) (2 arms), sponsored by Maxim Pharmaceuticals. Primary endpoint: Leukemia-Free Survival at 2.5 years. Started Jul 1998; status: completed.
02
Drugs
histamine dihydrochloride
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003991.